Nicholas James
Gordon McVie
REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
NICHOLAS JAMES, Birmingham University
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
A new drug has improved overall survival among patients with hormone resistant prostate cancer. The endothelin A antagonist ZD4054 was investigated in a placebo-controlled trial among 300 patients whose hormone-resistant prostate cancer had metastasized to bone.
NICHOLAS JAMES, Birmingham University
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
A new drug has improved overall survival among patients with hormone resistant prostate cancer. The endothelin A antagonist ZD4054 was investigated in a placebo-controlled trial among 300 patients whose hormone-resistant prostate cancer had metastasized to bone.
Jacek Jassem
David Cameron
EIxabepilone With Capecitabine: New Treatment Option For Patients Resistant to Anthracyclines and Taxanes?
REFERENCE: Abstract: 2101, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JACEK JASSEM, Medical University of Gdansk
COMMENT: DAVID CAMERON, UK National Cancer Research Network, Leeds
A combination of capecitabine and the anti-resistance agent, ixabepilone, has demonstrated a benefit over capecitabine alone for patients with breast cancer who develop resistance to anthracycline and taxane therapy.
JACEK JASSEM, Medical University of Gdansk
COMMENT: DAVID CAMERON, UK National Cancer Research Network, Leeds
A combination of capecitabine and the anti-resistance agent, ixabepilone, has demonstrated a benefit over capecitabine alone for patients with breast cancer who develop resistance to anthracycline and taxane therapy.
Anna Pavlick
Steven Novick
Oblimersen: Making Sense in Malignant Melanoma And Chronic Lymphocytic Leukemia?
REFERENCE: Abstracts: 7000 & 6004, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
ANNA PAVLICK, New York University Cancer Institute
STEVEN NOVICK, Genta Incorporated, Berkeley Heights, NJ
New data on the antisense drug oblimersen combined with standard chemotherapy in two different clinical settings: malignant melanoma, and chronic lymphocytic leukemia were presented at the ECCO conference.
ANNA PAVLICK, New York University Cancer Institute
STEVEN NOVICK, Genta Incorporated, Berkeley Heights, NJ
New data on the antisense drug oblimersen combined with standard chemotherapy in two different clinical settings: malignant melanoma, and chronic lymphocytic leukemia were presented at the ECCO conference.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
